Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Toxicol Appl Pharmacol. 2015 Apr 10;285(2):136–148. doi: 10.1016/j.taap.2015.03.029

Figure 2. Cyclophosphamide (CY)-induced cardiotoxicity in WT and GSTP-null mice.

Figure 2

(A) Plasma creatine kinase-MB (CK·MB ) levels in WT and GSTP-null mice 4h after CY (100-300 mg/kg, ip) treatment. Inset: Correlation between plasma CK·MB and CK levels (R2=0.96). (B) Heart wet weight:body weight ratio in WT and GSTP-null mice 24h post-CY (200 mg/kg) treatment. (C) Western blot analysis of albumin in cardiac lysates of saline or CY-treated WT and GSTP-null mice 4h after dosing. (D) GSH levels in hearts of CY-treated WT and GSTP-null mice 4h after CY (300 mg/kg). (E) Western blots and densitometric analysis of pro- and active caspase-3 in cardiac lysates of mice 4h after CY treatment at indicated doses. (F) Immunohistochemical staining and quantification of TUNEL positive cells (apoptosis-positive, indicated by arrows) in hearts of WT and GSTP-null mice 4h after saline or CY (200 mg/kg) treatment. Data are mean ± SEM (*p<0.05 vs. matched saline controls; #p<0.05 WT vs. GST-null; N=4-7 mice/group).